Abstract
improved PFS, OS, and 1-year survival was also observed in the BEVArm, but the trial was not powered to detect statistical significance for these outcomes. The BEV arm caused more toxic deaths in this high risk cohort of patients. Acknowledgment: This research was supported by the Spanish Healthcare Research Fund FIS Project, grant EC08/00071. Author Disclosure: S. Villa: K. Advisory Board; Roche Labs. C. Balana: K. Advisory Board; Roche Labs. A. Conde: None. A. Lucas: None. V. Rodriguez: None. M. Zurita: None. R. De Las Penas: K. Advisory Board; Roche labs.M. Gil: K. Advisory Board; Roche labs. J. Sepulveda: K. Advisory Board; Roche labs. R. Luque: None.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
